Results 41 to 50 of about 86,262 (260)

Immune thrombocytopenia

International journal of health sciences, 2022
An inherited condition with isolated thrombocytopenia, immune thrombocytopenia (ITP) is still unknown in terms of the cause. A primary or secondary ITP diagnosis is determined by whether or not an underlying treatable cause exists. Diagnosis of primary ITP is based on the exclusion and hence does not have a gold standard test to validate it.
Avijit Mazumder, Saumya Das, Ayush Atri, Komal Singh, Madhvi Singh   +4 more
openaire   +1 more source

Rheumatologic Manifestations of Patients With Type B Insulin Resistance

Arthritis Care &Research, EarlyView.
Objective The objectives of this study were to identify laboratory and clinical features associated with type B insulin resistance (TBIR), a rare condition caused by autoantibodies that inhibit the insulin receptor, most frequently occurring in the setting of systemic lupus erythematosus (SLE), and to increase awareness of this rare, life‐threatening ...
S. Amara Ogbonnaya, Sandra G. Williams, Raphael A. Kirou, Marissa Lightbourne, Rebecca J. Brown   +4 more
wiley   +1 more source

Cyclic thrombocytopenia with statistically significant neutrophil oscillations

Clinical Case Reports, 2018
Key Clinical Message Cyclic thrombocytopenia is often misdiagnosed as immune thrombocytopenia due to similar clinical features, a fact of significance because cyclic thrombocytopenia generally responds poorly to treatments used successfully in immune ...
Gabriel P. Langlois, Donald M. Arnold, Jayson Potts, Brian Leber, David C. Dale, Michael C. Mackey   +5 more
doaj   +1 more source

Building a Framework for Sexual and Reproductive Health Care in the Rheumatology Context: Content and Approaches

Arthritis Care &Research, EarlyView.
People with systemic autoimmune and rheumatic diseases (SARDs) are at higher risk than the general population of experiencing adverse pregnancy and perinatal outcomes such as preeclampsia, intrauterine growth restriction, and maternal and/or fetal death.
Mehret Birru Talabi, Sonya Borrero
wiley   +1 more source

From Payload‐First Toward Dual‐Mechanism Antibody–Drug Conjugates

Advanced Materials, EarlyView.
Conjugation converts potent antibodies into underexposed carriers. This perspective defines the antibody exposure deficit and maps a mechanism‐first design space from payload‐first to antibody‐first ADC architectures, integrating DAR, linker chemistry, and Fc engineering to guide rational design of constructs that balance targeted cytotoxicity with ...
Xavier Pivot, Sebastian Jung, Sébastien Harlepp, Alexandre Detappe   +3 more
wiley   +1 more source

The Epidemiology of Immune Thrombocytopenia

Canadian Journal of Infectious Diseases and Medical Microbiology, 1991
Three cases of immune thrombocytopenia (ITP) associated with human immunodeficiency virus (HIV) infection prompted a review of community‐acquired thrombocytopenia in Nova Scotia from January 1980 to December 1987. Two hundred and seven patients meeting the case definition of ITP were identified. The incidence of ITP rose from 2.0×105 in 1980 to 3.3×105
Walter F Schlech, Christine Nesdoly, Nancy Meagher, Janet Turner, Donalda Dickey   +4 more
openaire   +3 more sources

Pathological Mechanism‐Inspired Biomimetic Nano‐Senotherapy for Reversing Experimental Atherosclerosis in ApoE−/− Mice

Advanced Science, EarlyView.
The biomimetic self‐assembly nanomedicine reversing atherosclerosis via senotherapy strategy. ABSTRACT The greatest challenge in atherosclerosis (AS) management lies in achieving lesion reversal, not merely slowing progression. Senescent cell accumulation—driven by continuous generation and apoptotic resistance—perpetuates plaque pathology and ...
Yuhan Tian, Yanrui Yang, Qiuyu Li, Ying Hu, Qin Hu, Shasha Ran, Siyu Zhou, Xiujuan Yang, Shanshan Li, Qixiong Zhang   +9 more
wiley   +1 more source

Allosteric Inhibition of Polycomb Repressive Complex 2 by an EZH2‐Selective Small Molecule Inhibitor

Advanced Science, EarlyView.
The study characterizes C36, a highly selective EZH2/PRC2 inhibitor that acts via a novel allosteric mechanism. Unlike previous inhibitors, C36 inhibits EZH2/PRC2 by disrupting the allosteric communication between EZH2 and EED in a SAM‐noncompetitive manner.
Ting Cao, Dongdong Liu, Haishan Gao, Chenyang Qin, Wen Zhang, Ziyun Lu, Dongxia Tan, Yuxiu Qu, Yusong Liu, Zhiran Zou, Hongtao Yu, Wei Qi   +11 more
wiley   +1 more source

A likely unavoidable clinical scenario during treatment for venous thromboembolism complicated with severe immune thrombocytopenia: A case report

Clinical Case Reports, 2021
Patients with immune thrombocytopenia have increased risks of bleeding and thrombosis. The acute‐phase treatment for venous thromboembolism complicated with severe immune thrombocytopenia involves a “platelet dilemma” in therapeutic decision‐making.
Takaya Takeuchi, Yunosuke Matsuura, Yoshimasa Yamamura, Momoko Ohkusu, Shohei Koyama, Takeshi Kawaguchi, Mayumi Akaki Nagayasu, Hiroyuki Komatsu, Akihiko Okayama, Tetsunori Ishikawa, Tatsuya Atsumi, Kazuo Kitamura   +11 more
doaj   +1 more source

Redirecting Monocyte Differentiation With Engineered Extracellular Vesicles for Glioma Immunotherapy

Advanced Science, EarlyView.
A dual‐targeting engineered extracellular vesicles (M1‐CS‐EVs) platform is developed to redirect monocytes differentiation into anti‐tumor macrophages for glioma immunotherapy. This nanoplatform combines CAR‐mediated tumor recognition with localized CD47 blockade, leading to synergistic immune activation and potent suppression of tumor progression in ...
Yuanwei Pan, Xuan Liu, Qian‐Fang Meng, Lei Cao, Rongrong Li, Yangtao Xu, Jing Zhang, Chenchen Zhao, Lang Rao, Chen Yu   +9 more
wiley   +1 more source